Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

Suneeta’s research centers on identifying novel molecular signatures and biomarkers to improve the efficacy of cancer ...

Brad Axis Brain and Back Institute +1 (817) 502-7411 ... Visit us on social media: Facebook X LinkedIn YouTube ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 202 ...

Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sc ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), ...